Haemonetics director granted 2,538 restricted stock units
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Haemonetics Corp director Lloyd Emerson Johnson reported an equity compensation award of 2,538 shares of common stock in the form of restricted stock units (RSUs) on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU converting into one share of common stock when vested.
After this grant, Johnson’s directly held common stock position was reported as 15,471 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1, F2 | 2,538 | -- | -- |
Footnotes (2)
- F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
- F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Key Figures
Key Terms
restricted stock units ("RSUs") financial
contingent right financial
Long-Term Incentive Compensation Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Haemonetics (HAE) director Lloyd Emerson Johnson report?
What type of securities were granted to Lloyd Emerson Johnson in Haemonetics (HAE)?
What is the vesting schedule for Lloyd Emerson Johnson’s Haemonetics (HAE) RSUs?
Under what plan were the RSUs granted to Haemonetics (HAE) director Lloyd Emerson Johnson?
AI-generated analysis. How Rhea-AI works. Not financial advice.